Who
Jason Coloma V
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Maze Therapeutics; SVP, Chief Business Officer, Corvus Pharmaceuticals.
In numbers
- Trades disclosed
- 58
- Buys
- 0
- Sells
- 12
- Bought
- $0
- Sold
- $11.4M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 8 Jun 2016
- Last trade
- 1 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 May – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 2 Oct 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $70K2,593 at $27.02 | filing |
| 1 Oct 2026filed 2 Oct 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $862K31,908 at $27.02 | filing |
| 3 Sep 2026filed 4 Sep 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $293K11,282 at $26.01 | filing |
| 3 Sep 2026filed 4 Sep 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,325129 at $25.77 | filing |
| 3 Sep 2026filed 4 Sep 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $293K11,282 at $26.01 | filing |
| 3 Sep 2026filed 4 Sep 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,324129 at $25.77 | filing |
| 2 Sep 2026filed 4 Sep 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $260K9,852 at $26.38 | filing |
| 2 Sep 2026filed 4 Sep 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $37K1,375 at $27.12 | filing |
| 2 Sep 2026filed 4 Sep 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $260K9,852 at $26.38 | filing |
| 2 Sep 2026filed 4 Sep 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $37K1,375 at $27.12 | filing |
| 1 Sep 2026filed 3 Sep 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $68K2,593 at $26.31 | filing |
| 1 Sep 2026filed 3 Sep 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $839K31,908 at $26.29 | filing |
| 1 Sep 2026filed 3 Sep 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $68K2,593 at $26.31 | filing |
| 1 Sep 2026filed 3 Sep 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $839K31,908 at $26.29 | filing |
| 1 Sep 2026filed 3 Sep 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 3 Aug 2026filed 5 Aug 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $65K2,439 at $26.71 | filing |
| 3 Aug 2026filed 5 Aug 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $4,172154 at $27.09 | filing |
News
Maze Therapeutics (NASDAQ:MAZE) Stock Rated "Buy" in New Coverage at Canaccord Genuity GroupMAZE · themarketsdaily.com · 20 Oct 2026Head to Head Survey: Maze Therapeutics (NASDAQ:MAZE) vs. Cytokinetics (NASDAQ:CYTK)MAZE · dailypolitical.com · 18 Oct 2026Financial Review: Lisata Therapeutics (NASDAQ:LSTA) versus Maze Therapeutics (NASDAQ:MAZE)MAZE · dailypolitical.com · 15 Oct 2026
0 headlines in the last 90 days name Jason Coloma V; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.